NCT00061880View on ClinicalTrials.gov

BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

February 28, 2003

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2008

Conditions
Lymphoma
Interventions
DRUG

forodesine hydrochloride

Trial Locations (3)

27710

Duke Comprehensive Cancer Center, Durham

35294-3300

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY